Business
Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023
GARDEN CITY, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and
About this update from Beyond Air, Inc.
[{"type":"text","content":"GARDEN CITY, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in two upcoming investor conferences in March 2023. 35th Annual Roth Conference – March 12-14, 2023 Format: Fireside Chat Date: Monday, March 13, 2023 Participant: Steve Lisi, Chairman & CEO, Beyond Air Location: Laguna Niguel, CA Oppenheimer 33rd Annual Healthcare Conference – March 13-15, 2023 Format: Presentation Date & Time: Wednesday, March 15, 2023, at 9:20-9:50 AM ET Participant: Steve Lisi, Chairman & CEO, Beyond Air Location: Virtual presentation Webcast Link: Click Here Please contact your representative at either Roth or Oppenheimer to schedule a one-on-one meeting with Beyond Air during the respective conference. About Beyond Air®, Inc.Beyond Air is a medical device and biopharmaceutical company dedicated to harnessing the power of nitric oxide through its revolutionary NO Generator and Delivery System, LungFit, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company has received FDA approval for its first system, LungFit PH for persistent pulmonary hypertension of the newborn. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), nontuberculous mycobacteria (NTM) and severe lung infections in other settings. Additionally, Beyond Cancer, an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For mo...